NCT05063981View on ClinicalTrials.gov

Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP.

Active, not recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

November 25, 2021

Primary Completion Date

September 2, 2025

Study Completion Date

December 31, 2025

Conditions
AsthmaNasal PolypsSinusitis Chronic
Interventions
DRUG

Mepolizumab

Treatment with Mepolizumab could modify nasal, bronchial and systemic inflammation of patients with severe refractory eosinophilic asthma and nasal polyposis acting on disease control

Trial Locations (1)

82037

Istituti Clinici Scientifici Maugeri IRCCS, Telese Terme

All Listed Sponsors
lead

Istituti Clinici Scientifici Maugeri SpA

OTHER